TNGX Q4 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$42M

Net Income

-$39M

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$399M

Total Liabilities

$53M

Stockholders' Equity

$346M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$4M	-100.0%
Gross Profit	$0	$4M	-100.0%
Operating Income	-$42M	-$41M	-2.3%
Net Income	-$39M	-$38M	-2.9%